2015 was a big year for lung cancer immunotherapy, with two drugs approved as a second-line treatment for patients with non-small cell lung cancer. What does that mean? Previously a patient with non-small cell lung cancer, whose cancer progressed after being on treatment, wasn't left with very many options. Now, a number of those patients qualify to go on an immunotherapy drug.
↧